These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 2845169)

  • 1. [New technology of diagnosis of ovarian cancer].
    Terashima Y
    Gan No Rinsho; 1988 Aug; 34(10):1427-31. PubMed ID: 2845169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical value of a new serum tumor marker CA602 in ovarian cancers].
    Suzuki M; Sekiguchi I; Ohwada M; Aida I; Tamada T
    Nihon Gan Chiryo Gakkai Shi; 1990 Jul; 25(7):1454-60. PubMed ID: 2170549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A study of localizations and serum data; four tumor markers (CA125, CA19-9, CEA and TPA) in ovarian cancers].
    Kataoka A; Yakushiji M
    Nihon Gan Chiryo Gakkai Shi; 1990 Jan; 25(1):47-54. PubMed ID: 2157782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Tumor markers of ovarian cancer].
    Nozawa S
    Rinsho Byori; 1992 Apr; 40(4):349-53. PubMed ID: 1593759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Value of biological markers in the diagnosis and monitoring of cystadenocarcinoma].
    Bidart JM; Bellet D
    Rev Prat; 1989 Nov; 39(26):2317-20. PubMed ID: 2595221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical value of CA125, CA19-9, CEA, CA72-4, and TPA in borderline ovarian tumor.
    Tamakoshi K; Kikkawa F; Shibata K; Tomoda K; Obata NH; Wakahara F; Tokuhashi Y; Ishikawa H; Kawai M; Tomoda Y
    Gynecol Oncol; 1996 Jul; 62(1):67-72. PubMed ID: 8690294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The clinical usefulness of serum CA72-4 analysis in patients with ovarian cancer].
    Kobayashi H
    Nihon Sanka Fujinka Gakkai Zasshi; 1989 May; 41(5):585-9. PubMed ID: 2754289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Value of tumor markers in diagnosing and monitoring colorectal cancer and strategies for further improvement: analysis of 130 cases.
    Chen C; Chen LQ; Yang GL; Li Y
    Ai Zheng; 2007 Nov; 26(11):1221-6. PubMed ID: 17991322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Tumor marker--screening for gynecological cancer; personal experience. Utility of tumor markers in screening of ovarian cancer].
    Kimura E; Kobayashi S; Terashima Y
    Gan To Kagaku Ryoho; 1990 Dec; 17(12):2443-50. PubMed ID: 2260879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CA54/61 as a marker for epithelial ovarian cancer.
    Nozawa S; Aoki D; Yajima M; Tsukazaki K; Kobayashi T; Kimura E; Terashima Y; Inaba N; Takamizawa H; Negishi Y
    Cancer Res; 1992 Mar; 52(5):1205-9. PubMed ID: 1737381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Mucinous carcinoma-associated antigen (MCA) in ovarian cancer].
    Hanzal E; Kölbl H; Gitsch G; Bieglmayer C
    Gynakol Rundsch; 1990; 30 Suppl 1():68-70. PubMed ID: 2079303
    [No Abstract]   [Full Text] [Related]  

  • 12. [Clinical evaluation of serum CA-50 and CA 19-9 in gynecological tumors].
    Suzuki M; Ohwada M; Tamada T; Sakurabayashi I; Kawai T
    Rinsho Byori; 1989 Jul; 37(7):784-8. PubMed ID: 2558243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [An early detection of the recurrence of serous cystadenocarcinoma of the ovary with the tumor marker CA125 levels].
    Usui N; Suzuki M; Takada M
    Nihon Sanka Fujinka Gakkai Zasshi; 1992 Jun; 44(6):703-9. PubMed ID: 1506732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical factors and biomarkers in ovarian tumors development.
    Vrabie CD; Petrescu A; Waller M; Dina I
    Rom J Morphol Embryol; 2008; 49(3):327-38. PubMed ID: 18758637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Tumor marker CA 72-4 in ovarian cancer in comparison with CA 125 and D-dimer].
    Schelling M; Jänicke F; Senekowitsch R; Lörken A
    Gynakol Rundsch; 1991; 31 Suppl 2():286-9. PubMed ID: 1665138
    [No Abstract]   [Full Text] [Related]  

  • 16. Amplifications of proto-oncogenes in ovarian carcinoma.
    Bian M; Fan Q; Huang S; Ma J; Lang J
    Chin Med J (Engl); 1995 Nov; 108(11):844-8. PubMed ID: 8585978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The prognosis of ovarian cancer depends on the CA125 value at the end of induction therapy].
    Miwa K; Dozono H; Iemura K; Shinmura R; Nakamura Y; Matsumoto T; Ikeda S; Nagata Y
    Nihon Sanka Fujinka Gakkai Zasshi; 1991 May; 43(5):557-61. PubMed ID: 2056230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The values of urine cysteine protein activity in the diagnosis of ovarian cancer].
    Xi MR; Peng ZL; Cao ZY
    Zhonghua Fu Chan Ke Za Zhi; 1994 Feb; 29(2):85-7, 123. PubMed ID: 8033632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Significance of some tumor markers in differential diagnosis of ovarian tumor.
    Zakrzewska I; Borawska R; Poznański J; Maćkowiak B
    Rocz Akad Med Bialymst; 1999; 44():235-43. PubMed ID: 10697438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutation of K-ras protooncogene in human ovarian epithelial tumors of borderline malignancy.
    Mok SC; Bell DA; Knapp RC; Fishbaugh PM; Welch WR; Muto MG; Berkowitz RS; Tsao SW
    Cancer Res; 1993 Apr; 53(7):1489-92. PubMed ID: 8384077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.